Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.

Focus on

The management strategies that are currently available to manage bleeding events or urgent surgery in patients treated with NOACs

The clinical situations for which specific reversal agents to the NOACs may be useful and learn the advantages of such therapy as opposed to reversal strategies using unspecific haemostatic agents

The development and characteristics of idarucizumab, the specific reversal agent for dabigatran, of andexanet for the factor Xa inhibitors apixaban, rivaroxaban and edoxaban, and LWMH, and of aripazine or PER977 for both thrombin and factor Xa inhibitors

The results of pre-clinical studies investigating the use of NOACs in different bleeding models

How healthy volunteer studies have demonstrated the immediate, complete, and sustained reversal of NOAC-induced anticoagulation by one of the specific antidotes

How RE-VERSE AD, the patient study of idarucizumab in dabigatran-treated patients and ANNEXA, the patient study of andexanet in Xa inhibitor treated patients, may demonstrate the clinical value of the specific reversal strategy

Join Prof. Menno Huisman, Prof. Oliver Grottke and Dr. Jan Steffel for this EHRA webinar. This programme includes case based presentations, online assessments and discussions with these key opinion leaders and will give you some useful tips for your daily clinical practice.

Watch the webinar recording

Speakers

Professor Menno Huisman (speaker)

Thrombosis And Hemostasis

Leiden University Medical Center

Netherlands

Prof Oliver Grottke (speaker)

Dept Anesthesiology

Rwth University Hospital Aachen

Germany

Dr Jan Steffel (host)

Co-chair, Electrophysiology and Pacing

University Hospital Zurich

Switzerland

Session information

Target audience : This webinar addresses EHRA members and cardiologists working in the field of arrhythmias.

During the webinar, you will be able to send your questions by chat and interact with our key opinion leaders who will provide feedback live.

How to access the live webinar?

Upon registration, you will receive a confirmation email with the connection details. Please check your spam if you do not receive any email or contact us.

Technical settings

The webinar is available on PC and Tablets. The use of smartphone is not recommended. For the best viewing experience, a high speed Internet connection is recommended (minimum 2Mbps). Please make sure that the firewall does not prevent the connection to the webinar.